高血压患者RAAS活性及其对降压治疗的影响
[Abstract]:OBJECTIVE: To investigate the plasma renin-angiotensin-aldosterone system (RAAS) activity and its correlation with target organ damage in patients with essential hypertension in China, and to study the effect of antihypertensive drugs on antihypertensive therapy by detecting plasma renin, angiotensin II and aldosterone activity. Methods: A total of 504 patients with essential hypertension, 186 males and 318 females, were enrolled in the Department of cardiovascular medicine from June 2012 to December 2014 according to the inclusion criteria. The levels of low density lipoprotein cholesterol (LDL-C), uric acid, serum creatinine, basic plasma renin activity (PRA), angiotensin II (Ang II), aldosterone (ALD) were measured. The patients were examined for stroke by CT, carotid plaque by carotid artery Doppler, and cardiac ultrasonography. The risk factors of stroke, carotid plaque, left ventricular hypertrophy and renal damage were screened by logistic regression analysis, including PRA, Ang II, ALD, age, sex, blood pressure, hypertension course, uric acid and LDL-C. ACEI and ARB were preferred for patients with elevated PRA and Ang II, aldosterone receptor antagonists were preferred for patients with elevated ALD, CCB and thiazide diuretics were preferred for patients with low PRA and Ang II, and the antihypertensive drugs were recorded in detail before admission and according to PRA, Ang II and ALD levels. Results: 1. A total of 504 hypertensive patients, aged 19-95 (69.97 + 12.50) years, including 186 males and 318 females, were enrolled in this study. Compared with the low PRA group, the hypertension course of the high PRA group was shorter (7.30 9.31 6550 The results of correlation analysis showed that PRA and ALD were negatively correlated with age, while PRA, Ang II and ALD were positively correlated with LDL-C. 5. Logistic regression analysis showed that the increase of PRA was an independent risk factor for LVH (OR = 2.42, 95% CI: 1.32-4.42, P 0.05). Risk factors (OR = 2.88, 95% CI: 1.45-5.70, P 0.05). 6. With the increase of RAAS grade, the use of angiotensin converting enzyme inhibitor (ACEI) / angiotensin receptor antagonist (ARB) and aldosterone antagonist gradually increased, while the use of diuretics, calcium antagonist (CCB) gradually decreased, and the overall type of drug selection in hypertension. In accordance with the RAAS level, the rate of blood pressure reaching the standard was 93.7%, and the ideal hypotensive effect was obtained. Conclusion: 1. The RAAS level was generally low in essential hypertension. 2. Age was negatively correlated with ALD level, and LDL-C was positively correlated with RAAS activity. 3. The independent risk factors of LVH in hypertension patients included high PRA, past highest blood pressure and so on. Levels of Ang II and ALD had no significant correlation with LVH; independent risk factors for stroke included high PRA, the highest blood pressure level and age at admission, and there was no significant correlation between Ang II and ALD levels and stroke; independent risk factors for carotid plaque events in hypertensive patients included gender, hypertension duration and age, while RAAS levels and carotid plaque. The independent risk factors of renal impairment in hypertensive patients include hyperuricemia, hypertension course and age, while the level of RAAS has no significant relationship with the occurrence of renal impairment.
【学位授予单位】:暨南大学
【学位级别】:硕士
【学位授予年份】:2015
【分类号】:R544.1
【相似文献】
相关期刊论文 前10条
1 赖西南,刘荫秋,陈洪;高速钢珠弹伤时血浆ANP和RAAS变化因素探讨[J];第三军医大学学报;1990年03期
2 李洁;何继瑞;;胰腺RAAS系统激活的生物效应及阻断方法研究进展[J];中国现代医药杂志;2011年05期
3 曹家麟;朱小区;吴春明;欧阳钦;苏林红;;腹水超滤浓缩回输对肝硬化腹水患者血浆白蛋白和RAAs的影响[J];浙江实用医学;2008年02期
4 尚文斌;高燕;叶丽芳;余江毅;;初发2型糖尿病患者血清RAAS特性的初步分析[J];实用糖尿病杂志;2013年05期
5 杨晋辉;钮振;余曙光;;肝硬化与RAAS[J];昆明医学院学报;1993年02期
6 马宇虹;李广平;刘彤;邢艇;袁如玉;车京津;许纲;;RAAS激活与急性心肌梗死早期新发房颤的关系[J];山东医药;2010年04期
7 于秀峙,路建饶;血压正常或高血压病人使用β肾上腺素能受体阻断疗法可抑制肾素-血管紧张素-醛固酮系统(RAAS)[J];国外医学(内科学分册);2000年08期
8 杨鹏;李云;吴寿岭;王丽晔;刘秀荣;赵丹丹;武英;陈锐;李发飞;;长期服用氢氯噻嗪后RAAS活性变化与血糖变化关系[J];中国药房;2010年16期
9 柳威;田维;蔡晓月;王子旭;汪涛;赵英强;;从PPAR信号调节及中药治疗重新认识RAAS系统[J];中国分子心脏病学杂志;2011年02期
10 张琪;倪兆慧;;RAAS阻滞剂在老年慢性肾脏病中应用的研究进展[J];中华肾病研究电子杂志;2014年02期
相关会议论文 前4条
1 朱明军;栗晓乐;王幼平;谢世阳;王永霞;李彬;王贺;;加参优化方对大鼠心梗后梗死范围及RAAS的影响[A];第三届“黄河心血管病防治论坛”资料汇编[C];2012年
2 张宏;;足剂量RAAS抑制剂在高血压治疗中的重要意义 雅施达~汶8mg[A];玉溪市医学会心血管内科专业委员会成立大会暨第五届玉溪心脏论坛论文集[C];2011年
3 谌贻璞;;抗RAAS与肾脏保护研究进展(提纲)[A];中华医学会肾脏病学分会2006年学术年会专题讲座[C];2006年
4 于汇民;林曙光;;RAAS基因多态性与ACEIs降压疗效相关性研究的进展与展望[A];中华医学会第十三次全国心血管病学术会议专题报告专辑[C];2011年
相关硕士学位论文 前10条
1 李小斌;高血压患者RAAS活性及其对降压治疗的影响[D];暨南大学;2015年
2 刘婷婷;2型糖尿病合并高血压患者的盐敏感性与RAAS的关系[D];中南大学;2011年
3 孙静;暖心胶囊对慢性心衰患者RAAS干预的临床研究[D];广州中医药大学;2006年
4 穆敏;婴幼儿阵发性室上性心动过速的心率变异性及其与RAAS变化的关系[D];山东大学;2008年
5 梁灿;心衰2号方对心衰血瘀证型患者RAAS系统的影响研究[D];广州中医药大学;2009年
6 郭旭;RAAS系统拮抗剂对自发性高血压大鼠足细胞Nephrin表达和肾脏保护作用的影响[D];中国医科大学;2010年
7 闫纪强;福辛普利干预对糖尿病大鼠胰腺RAAS、氧化应激及胰岛功能的影响[D];重庆医科大学;2009年
8 陈慧;芪参益气滴丸治疗心衰大鼠炎症反应及RAAS系统激活的实验研究[D];北京中医药大学;2015年
9 郝莹;肥胖性高血压患者血清瘦素水平与RAAS、胰岛素敏感性相关性研究[D];中国医科大学;2004年
10 焦方杰;慢性心衰大鼠下丘脑室旁核炎性细胞因子与RAAS的变化[D];泰山医学院;2013年
,本文编号:2221303
本文链接:https://www.wllwen.com/yixuelunwen/xxg/2221303.html